Evaluation of the Effects of Fluid Therapy on Respiratory Mechanics
NCT ID: NCT02071524
Last Updated: 2016-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2013-09-30
2017-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* patients undergoing elective abdominal, thoracic, vascular surgery
* minimum age 18 years
* informed consent
Exclusion Criteria:
* patients with severe cardiomyopathy or severe heart failure
* history of coagulation disorders
* patients with severe cardiovascular or respiratory disorders
* renal insufficiency
Respiratory mechanic parameters (i.e., inspiratory peak pressure, plateau pressure, total airway resistance, and static compliance) are obtained .Blood samples are drawn simultaneously from the arterial catheters for gas analysis. Data were collected after induction of anesthesia (T0) after 1 h (T1), 2 h (T2), 3 h (T3) and at the end of surgery.
Primary outcome: evaluate the fluids effects on oxygenation, respiratory mechanics
Secondary outcome: Incidence of surgery related complications
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cristalloid
group cristalloid (ringer lactate)
Cristalloid administration
Only Ringer Lactate administration
colloids
colloid: cristalloid in according to cardiac output
Group Colloid
Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group Colloid
Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
Cristalloid administration
Only Ringer Lactate administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* minimum age 18 years
* informed consent
Exclusion Criteria
* history of coagulation disorders
* patients with severe cardiovascular or respiratory disorders
* renal insufficiency
* severe liver diseases
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Università degli Studi di Ferrara
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Savino Spadaro
Researcher
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Ferrara
Ferrara, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Carlo A Volta, professor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22012014
Identifier Type: -
Identifier Source: org_study_id